
Xuan Marian Thai
Supervisory Patent Examiner (ID: 11238, Phone: (571)272-7147 , Office: P/3715 )
| Most Active Art Unit | 3715 |
| Art Unit(s) | 3403, 2111, 3713, 3715, 3714, 2781, 2181, 2782 |
| Total Applications | 777 |
| Issued Applications | 392 |
| Pending Applications | 173 |
| Abandoned Applications | 214 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 8976045
[patent_doc_number] => 20130209475
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2013-08-15
[patent_title] => 'DKK1 ANTIBODIES AND METHODS OF USE'
[patent_app_type] => utility
[patent_app_number] => 13/878619
[patent_app_country] => US
[patent_app_date] => 2011-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 42347
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 8
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13878619
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/878619 | DKK1 antibodies and methods of use | Oct 26, 2011 | Issued |
Array
(
[id] => 8405950
[patent_doc_number] => 20120238013
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-09-20
[patent_title] => 'FUSION PARTNER FOR PRODUCTION OF MONOCLONAL RABBIT ANTIBODIES'
[patent_app_type] => utility
[patent_app_number] => 13/274946
[patent_app_country] => US
[patent_app_date] => 2011-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 7215
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13274946
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/274946 | Fusion partner for production of monoclonal rabbit antibodies | Oct 16, 2011 | Issued |
Array
(
[id] => 10001468
[patent_doc_number] => 09045547
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2015-06-02
[patent_title] => 'Methods of using antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)'
[patent_app_type] => utility
[patent_app_number] => 13/251909
[patent_app_country] => US
[patent_app_date] => 2011-10-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 152
[patent_figures_cnt] => 163
[patent_no_of_words] => 73085
[patent_no_of_claims] => 66
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 90
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13251909
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/251909 | Methods of using antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) | Oct 2, 2011 | Issued |
Array
(
[id] => 7754615
[patent_doc_number] => 20120027765
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-02-02
[patent_title] => 'ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)'
[patent_app_type] => utility
[patent_app_number] => 13/252016
[patent_app_country] => US
[patent_app_date] => 2011-10-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 152
[patent_figures_cnt] => 152
[patent_no_of_words] => 72986
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 8
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0027/20120027765.pdf
[firstpage_image] =>[orig_patent_app_number] => 13252016
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/252016 | ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) | Oct 2, 2011 | Abandoned |
Array
(
[id] => 8152492
[patent_doc_number] => 08168762
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2012-05-01
[patent_title] => 'Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)'
[patent_app_type] => utility
[patent_app_number] => 13/251955
[patent_app_country] => US
[patent_app_date] => 2011-10-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 152
[patent_figures_cnt] => 163
[patent_no_of_words] => 73122
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/08/168/08168762.pdf
[firstpage_image] =>[orig_patent_app_number] => 13251955
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/251955 | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) | Oct 2, 2011 | Issued |
Array
(
[id] => 8056457
[patent_doc_number] => 20120077964
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-03-29
[patent_title] => 'ANTAGONISTS OF PCSK9'
[patent_app_type] => utility
[patent_app_number] => 13/246219
[patent_app_country] => US
[patent_app_date] => 2011-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 20958
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0077/20120077964.pdf
[firstpage_image] =>[orig_patent_app_number] => 13246219
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/246219 | ANTAGONISTS OF PCSK9 | Sep 26, 2011 | Abandoned |
Array
(
[id] => 8577904
[patent_doc_number] => 08344114
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2013-01-01
[patent_title] => 'Antagonists of PCSK9'
[patent_app_type] => utility
[patent_app_number] => 13/242744
[patent_app_country] => US
[patent_app_date] => 2011-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 20971
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 120
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13242744
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/242744 | Antagonists of PCSK9 | Sep 22, 2011 | Issued |
Array
(
[id] => 8094141
[patent_doc_number] => 20120082680
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-04-05
[patent_title] => 'ANTAGONISTS OF PCSK9'
[patent_app_type] => utility
[patent_app_number] => 13/242831
[patent_app_country] => US
[patent_app_date] => 2011-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 20961
[patent_no_of_claims] => 37
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0082/20120082680.pdf
[firstpage_image] =>[orig_patent_app_number] => 13242831
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/242831 | ANTAGONISTS OF PCSK9 | Sep 22, 2011 | Abandoned |
Array
(
[id] => 8054111
[patent_doc_number] => 20120076799
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-03-29
[patent_title] => 'ANTAGONISTS OF PCSK9'
[patent_app_type] => utility
[patent_app_number] => 13/242809
[patent_app_country] => US
[patent_app_date] => 2011-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 20959
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0076/20120076799.pdf
[firstpage_image] =>[orig_patent_app_number] => 13242809
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/242809 | ANTAGONISTS OF PCSK9 | Sep 22, 2011 | Abandoned |
Array
(
[id] => 10076309
[patent_doc_number] => 09114144
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2015-08-25
[patent_title] => 'Kallikrein-inhibitor therapies'
[patent_app_type] => utility
[patent_app_number] => 13/228300
[patent_app_country] => US
[patent_app_date] => 2011-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 20212
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 248
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13228300
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/228300 | Kallikrein-inhibitor therapies | Sep 7, 2011 | Issued |
Array
(
[id] => 7742259
[patent_doc_number] => 20120020962
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-01-26
[patent_title] => 'METHOD OF DEPLETING REGULATORY T CELL'
[patent_app_type] => utility
[patent_app_number] => 13/225811
[patent_app_country] => US
[patent_app_date] => 2011-09-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 17897
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0020/20120020962.pdf
[firstpage_image] =>[orig_patent_app_number] => 13225811
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/225811 | METHOD OF DEPLETING REGULATORY T CELL | Sep 5, 2011 | Abandoned |
Array
(
[id] => 9895088
[patent_doc_number] => 20150050287
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2015-02-19
[patent_title] => 'ANTI-CXCL13 ANTIBODIES AND METHODS OF USING THE SAME'
[patent_app_type] => utility
[patent_app_number] => 13/820278
[patent_app_country] => US
[patent_app_date] => 2011-09-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 33
[patent_figures_cnt] => 33
[patent_no_of_words] => 39852
[patent_no_of_claims] => 64
[patent_no_of_ind_claims] => 19
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13820278
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/820278 | Anti-CXCL13 antibodies and methods of using the same | Aug 31, 2011 | Issued |
Array
(
[id] => 9895088
[patent_doc_number] => 20150050287
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2015-02-19
[patent_title] => 'ANTI-CXCL13 ANTIBODIES AND METHODS OF USING THE SAME'
[patent_app_type] => utility
[patent_app_number] => 13/820278
[patent_app_country] => US
[patent_app_date] => 2011-09-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 33
[patent_figures_cnt] => 33
[patent_no_of_words] => 39852
[patent_no_of_claims] => 64
[patent_no_of_ind_claims] => 19
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13820278
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/820278 | Anti-CXCL13 antibodies and methods of using the same | Aug 31, 2011 | Issued |
Array
(
[id] => 7650800
[patent_doc_number] => 20110300069
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-12-08
[patent_title] => ' Methods of Using Labeled Ligands Having Human CD4 Specificity'
[patent_app_type] => utility
[patent_app_number] => 13/211414
[patent_app_country] => US
[patent_app_date] => 2011-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 8565
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0300/20110300069.pdf
[firstpage_image] =>[orig_patent_app_number] => 13211414
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/211414 | Methods of Using Labeled Ligands Having Human CD4 Specificity | Aug 16, 2011 | Abandoned |
Array
(
[id] => 7652067
[patent_doc_number] => 20110301336
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-12-08
[patent_title] => 'ANTIBODY PRODUCED USING OSTRICH AND METHOD FOR PRODUCTION THEREOF'
[patent_app_type] => utility
[patent_app_number] => 13/210512
[patent_app_country] => US
[patent_app_date] => 2011-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 6603
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0301/20110301336.pdf
[firstpage_image] =>[orig_patent_app_number] => 13210512
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/210512 | Method for production of antibody using ostrich | Aug 15, 2011 | Issued |
Array
(
[id] => 7650876
[patent_doc_number] => 20110300145
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-12-08
[patent_title] => 'Interferon Alpha Antibodies And Their Uses'
[patent_app_type] => utility
[patent_app_number] => 13/211092
[patent_app_country] => US
[patent_app_date] => 2011-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 30425
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 15
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0300/20110300145.pdf
[firstpage_image] =>[orig_patent_app_number] => 13211092
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/211092 | Interferon alpha antibodies and their uses | Aug 15, 2011 | Issued |
Array
(
[id] => 7650884
[patent_doc_number] => 20110300153
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-12-08
[patent_title] => 'ANTIBODY PRODUCED USING OSTRICH AND METHOD FOR PRODUCTION THEREOF'
[patent_app_type] => utility
[patent_app_number] => 13/210516
[patent_app_country] => US
[patent_app_date] => 2011-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 6599
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0300/20110300153.pdf
[firstpage_image] =>[orig_patent_app_number] => 13210516
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/210516 | Method of producing anti-CD166 antibody in ostrich | Aug 15, 2011 | Issued |
Array
(
[id] => 7776317
[patent_doc_number] => 20120039895
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-02-16
[patent_title] => 'PHOSPHORYCHOLINE CONJUGATES AND CORRESPONDING ANTIBODIES'
[patent_app_type] => utility
[patent_app_number] => 13/208138
[patent_app_country] => US
[patent_app_date] => 2011-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 8755
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0039/20120039895.pdf
[firstpage_image] =>[orig_patent_app_number] => 13208138
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/208138 | PHOSPHORYCHOLINE CONJUGATES AND CORRESPONDING ANTIBODIES | Aug 10, 2011 | Abandoned |
Array
(
[id] => 8903660
[patent_doc_number] => 20130171163
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2013-07-04
[patent_title] => 'Inhibition of LAR Phosphatase to Enhance Therapeutic Angiogenesis'
[patent_app_type] => utility
[patent_app_number] => 13/813964
[patent_app_country] => US
[patent_app_date] => 2011-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 20
[patent_no_of_words] => 30406
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13813964
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/813964 | Inhibition of LAR Phosphatase to Enhance Therapeutic Angiogenesis | Aug 4, 2011 | Abandoned |
Array
(
[id] => 7754469
[patent_doc_number] => 20120027686
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-02-02
[patent_title] => 'HK1-BINDING PROTEINS'
[patent_app_type] => utility
[patent_app_number] => 13/192786
[patent_app_country] => US
[patent_app_date] => 2011-07-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 54297
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0027/20120027686.pdf
[firstpage_image] =>[orig_patent_app_number] => 13192786
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/192786 | HK1-BINDING PROTEINS | Jul 27, 2011 | Abandoned |